Tag: drug pricing

drug pricing

Washington Focus

Marketing Tax, Pricing Limits, Other Measures May Pass as Add-ons to Omnibus Bills

Marketing Tax, Pricing Limits, Other Measures May Pass as Add-ons to Omnibus Bills

Jan. 5, 2021 – The just-enacted COVID-19 relief bill may be a harbinger of what is to come in 2021 for drug pricing and marketing tax proposals, according to Coalition for Healthcare Communication Executive Director Jon Bigelow. In a memo to Coalition members and industry leaders, Bigelow noted that it had been fairly clear weeks […]

Read more

Washington Focus

Biden Plans Include Key Healthcare Appointments, ACA and, Maybe, Drug Pricing

Biden Plans Include Key Healthcare Appointments, ACA and, Maybe, Drug Pricing

Dec. 7, 2020 – President-elect Joe Biden announced on Dec. 7 his plans for filling key public health positions, including nominations for California Attorney General Xavier Becerra to be the next secretary of Health and Human Services and Dr. Rochelle Walensky, currently an infectious disease specialist at Massachusetts General Hospital, to become director of the […]

Read more

Washington Focus

Movement in White House-Pharma Industry Standoff on Drug Pricing?

Movement in White House-Pharma Industry Standoff on Drug Pricing?

Aug. 31, 2020 – Following the Democratic and Republican convention attacks on big pharma and President Trump’s acceptance speech for his party’s nomination for re-election – in which he claimed to have already taken effective action to lower prescription drug prices through Executive Orders  – the Pharmaceutical Research and Manufacturers of America (PhRMA) is making […]

Read more

Washington Focus

Trump’s Drug Pricing Executive Orders Unlikely to Have Immediate Effect

Trump’s Drug Pricing Executive Orders Unlikely to Have Immediate Effect

July 27, 2020 – The four Executive Orders signed by President Trump on Friday were designed to address drug pricing concerns, but their combined impact is modest and they are “unlikely to have any immediate effect,” according to Coalition for Healthcare Communication Executive Director Jon Bigelow. However, they do “give the president talking points for […]

Read more

Legislative

Pharma Reputation on the Line During COVID-19 Crisis

Pharma Reputation on the Line During COVID-19 Crisis

June 29, 2020 – After being scrutinized for years regarding drug pricing issues, the biopharma industry is enjoying a boost in public opinion during the COVID-19 crisis. However, that boost may slowly be fading as lawmakers and the public continue to be skeptical of the industry, as evidenced by two bills introduced in the House […]

Read more

Legislative

Senators Push New Bill to Require Drug List Prices in Ads After Regulation Set Aside by Court

Senators Push New Bill to Require Drug List Prices in Ads After Regulation Set Aside by Court

Nov. 11, 2019 – As Congress works to agree on legislation that would rein in drug prices, a bill co-sponsored by Sen. Charles Grassley (R-Iowa) and Sen. Dick Durbin (D-Ill.) – which would require that list prices be included in direct-to-consumer (DTC) television advertisements – may be close to a vote. Grassley and Durbin hoped […]

Read more

Regulatory/FDA

FDA Amps Up Foreign Inspections Under Pressure to Bend on Opposition to Drug Importation

FDA Amps Up Foreign Inspections Under Pressure to Bend on Opposition to Drug Importation

Sept. 25, 2019 – The traditional position of FDA’s leadership that the importation of foreign medicines is illegal and may pose safety risks to American patients appears to be in conflict with the Trump administration and other politicians who believe importation to be a key element of lowering prescription drug costs. Now, the agency is […]

Read more

Courts/First Amendment

Three Manufacturers and ANA File Suit against CMS over Drug Price Disclosure Rule

Three Manufacturers and ANA File Suit against CMS over Drug Price Disclosure Rule

June 17, 2019 – The Trump administration’s final rule mandating that drug companies include the wholesale acquisition cost (WAC) in direct-to-consumer (DTC) television ads for many drugs “exceeds [the Department of Health and Human Services’ (HHS’)] statutory authority, violates the First Amendment, and should therefore be set aside,” according to a lawsuit filed Friday, less […]

Read more

Washington Focus

Rawson: Drug Pricing Concerns Will Dominate in Run-up to 2020 Election

Rawson: Drug Pricing Concerns Will Dominate in Run-up to 2020 Election

May 23, 2019 – Concern over drug pricing remains a healthcare policy issue that enjoys bipartisan support and will remain on the table for the Trump administration and Congress as campaigns for the 2020 election ramp up, according to Kate Rawson, senior editor at Prevision Policy. Speaking at a session of the Coalition for Healthcare […]

Read more

DTC Advertising

Despite Industry’s Price Transparency Initiatives, CMS Pushes Proposed Rule Forward

Despite Industry’s Price Transparency Initiatives, CMS Pushes Proposed Rule Forward

April 8, 2019 – The first television ads including drug price information are hitting the airwaves, reinforcing the point that list price is a highly misleading metric, and Pharmaceutical Research and Manufacturers of America (PhRMA) members are preparing to voluntarily refer consumers to online drug pricing information in their drug ads within a few weeks. […]

Read more